Our Exits

adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species.
Antibody selection is based on a novel fully synthetic, dog-specific phage display library that allows de-novo identification of antibodies to select a drug candidate with optimal properties.
adivo is a spin-off from MorphoSys AG, a leading European biopharmaceutical company. The team transfers an in-depth expertise in discovery and development of human therapeutic antibodies to the veterinary market.

memetis develops foil-based miniature actuators made of shape memory alloys (SMA). SMA are metallic alloys that seem to "remember" a certain shape by electric heating that has been trained beforehand and then assume it independently. The alloy already disposes of these properties, so that no further mechanical components are required. memetis actuators thus enable high switching forces with better integration and higher flexibility compared to conventional solutions. memetis has the expertise to quickly adapt the developed actuators to customer requirements. Due to the extended range of applications, memetis actuators are used in a multitude of innovative industries and sectors.

The founders of Kumovis GmbH have set themselves the goal of enabling the additive production of plastic implants and are developing innovative 3D printers specifically for medical products. Kumovis focuses on the processing of high-performance polymers, which are already established in medical technology. With the Kumovis system these plastics can be processed individually, decentrally and with a high degree of design freedom. Through the integration of a unique air circuit including filter units, the technology enables a clean room environment within the build chamber. The contamination of the component with foreign particles can be avoided. As a result, the Kumovis printer can produce products such as implants cost-effectively and at the same time patient-individualized.

Hofmann & Stirner Zuführsysteme GmbH was founded in 2016 by Daniel Hofmann and Florian Stirner. The company develops powerful and flexible feeding systems using digital twins and artificial intelligence. Hofmann & Stirner work closely together with well-known companies in machine and plant construction.
More: www.designforfeeding.com

reINVENT is a Munich-based provider of construction software. The solution offers 15 features that connect all stakeholders during the entire lifecycle of construction projects on a centralized platform. reINVENT’s mission is to bring construction processes to the digital century and make a difference through facilitating communication, collaboration, and exchange of data to save time and money.

C2S2 digitizes corporate policies with an innovative linguistic approach and communicates them via the C2S2® Rulebook Dialogue-Platform, so that employees receive practical decision-making assistance across all regulations. The competence gained in this way helps companies and employees to act responsibly and in line with corporate values and to efficiently minimize risks.

Modern therapeutic approaches face the challenge to combine efficacy, low undesired side effects and reasonable pricing. Therefore, drug substances become more and more complex, therapies become more personalized while overall life-cycle costs from drug discovery up to the manufacturing of the final therapeutic are on trial.
Peptides – or short proteins - represent a promising therapeutic class, and Belyntic’s PEC technology offers an innovative solution for their manufacturing. The linker-based approach enables parallel, efficient and highly selective purification and modification of chemically synthesized peptides. Belyntic offers kit products as well as cooperation projects and custom services for research institutions, custom peptide manufacturers as well as biotech and pharma companies.

Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat
Problem: Solid cancers are still very difficult to treat. Most treatments increase life expectancy, but only a few lead to a complete cure. Antibody drug conjugates (ADCs) have proven to be a promising therapeutic approach, but still cause significant and toxic side effects.

The solution: Emergence Therapeutics has identified several areas where ADCs can be improved. These are the antibody itself, the toxin used to kill the cancer cell, and the linker that couples the toxin to the antibody.

Technology/ IP: The antibody-related IP is in-licensed from the University of Aix-Marseille (France) and the toxin-related IP is in-licensed from Heidelberg Pharma.
The IP and all results generated for the ADC in development will be out-licensed or sold by Emergence.

LOEWI GmbH is a scientific spin-off of the TU München with the mission to make personalized health and nutrition available to everyone by combining science and technology. LOEWI's patented personalization concept analyzes health relevant data of customers and patients, makes the analysis available via LOEWI's Health Profile (Medical Software Class I), and creates personalized nutrient recommendations and therapies using a sophisticated recommendation algorithm, which are 100% tailored to the personal needs of each customer and patient.

Natif.ai is a deep-tech start-up in the field of intelligent document process automation (IDP). Thanks to high-performance AI models and a self-developed Deep-OCR, a wide variety of documents can be analyzed extremely quick, accurate and relevant data is extracted. Natif.ai provides a fast and efficient way to productively bring artificial intelligence into the economy. It was founded by a German-French team and is an official spin-off of the German Research Institute for Artificial Intelligence (DFKI).

Betterfront is a Munich-based investment technology company dedicated to alternative investments. Our end-to-end fundraising and data analytics platform helps fund managers attract, engage and retain institutional investors.

lino Biotech AG was incorporated as a ETH Zurich spin-out in Zürich, Switzerland, in March 2020, and is venture backed by Roche Venture Fund, High-Tech Gründerfonds and several lifescience family offices. lino offers industry partners and researchers a unique way to study molecular interactions in living cells and crude biosystems.

Hamburg-based Etvas GmbH was founded in December 2019 by financial services expert Sören Timm and IT entrepreneur Ilie Ghiciuc. Etvas is the world's first digital B2B2C marketplace for additional services from various providers that add value to the products and services of banks and insurance companies. With just one API, banks and insurance companies have quick access to all services on the Etvas marketplace thanks to the platform technology, which creates highly personalized customer experiences through a variety of relevant services. This customer engagement platform ensures better monetization of customer relationships while keeping implementation and usage costs low and customer retention high. Etvas partners can thus increase their market share.

In early 2019, Etvas' innovative service platform was awarded funding from the InnoFounder program of Hamburg-based IFB Innovationsstarter GmbH. Subsequently, Etvas received INVEST accreditation from the BMWi. In October of the same year, Etvas achieved a place in the fifth batch of the Next Commerce Accelerator. One of the first customers is Sparkasse Bremen, which offers its customers added value through individually tailored additional services.

The Leipzig startup was founded in 2017 by Robin Maier, Lukas Stenzel and David Schumann and shortly afterwards was accepted to the SpinLab Startup Accelerator. Since then, clients such as BOSCH and AOK PLUS have been acquired. At the end of last year, a cooperation agreement was also concluded with a German health insurance company. MINDANCE clients thus receive a financial subsidy of up to 100% for the use of MINDANCE. This year this model is to be rolled out on a large scale in cooperation with other health insurance companies.

tech11 was founded in 2018 by Pierre Dubosq and Matthias Reining in Würzburg, Germany. The company grew to over 40 employees already in its third year of existence and reached seven-digit sales figures in a short time. Last year, a branch office was already opened in Cologne, and more are to follow this year to be able to hire future employees at multiple locations.